Bayer
NEWS
Bayer is moving closer to a $10 billion settlement over the Roundup lawsuits and the company is in the midst of restructuring.
Bayer and Meiogenix, a biotech company focused on next-generation breeding technologies, announced a collaboration to advance agricultural research and development by accelerating the development of Meiogenix’s proprietary technologies related to plant breeding and genome editing applications.
It was another busy week for clinical trial updates. Here’s a look.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities,” said Chris Chen, chief executive officer of WuXi Biologics.
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
As usual, it was a busy week for clinical trial updates. Here’s a look.
JOBS
IN THE PRESS